These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3063778)

  • 1. Tumor necrosis factor: how to improve the antitumor activity and decrease accompanying side effects for therapeutic application.
    Haranaka K
    J Biol Response Mod; 1988 Dec; 7(6):525-34. PubMed ID: 3063778
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of tissue factor in the antitumor effect of recombinant human tumor necrosis factor-alpha in mice.
    Nishigaki F; Miyayasu K; Tsujimoto S; Manda T; Shimomura K
    Anticancer Res; 1994; 14(6B):2573-6. PubMed ID: 7872683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erythropoietin prevents oxidative stress and lipid peroxidation process in human umbilical vein endothelial cells induced by tumor necrosis factor alpha].
    Szczepański M; Kamianowska M; Wnuczko K; Skrzydlewska E; Wołczyński S
    Pol Merkur Lekarski; 2006 Dec; 21(126):534-9. PubMed ID: 17405292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.
    Satomi N; Sakurai A; Haranaka R; Haranaka K
    J Biol Response Mod; 1988 Feb; 7(1):54-64. PubMed ID: 3373234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.
    Gasparri A; Moro M; Curnis F; Sacchi A; Pagano S; Veglia F; Casorati G; Siccardi AG; Dellabona P; Corti A
    Cancer Res; 1999 Jun; 59(12):2917-23. PubMed ID: 10383155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies.
    de Vries MR; ten Hagen TL; Marinelli AW; Eggermont AM
    Anticancer Res; 2003; 23(2C):1811-23. PubMed ID: 12820463
    [No Abstract]   [Full Text] [Related]  

  • 7. Cloning, expression, purification of rat tumor necrosis factor and demonstration of its antitumor activity in Bomirski amelanotic melanoma.
    Koszałka P; Breza H; Bigda J
    Neoplasma; 1998; 45(3):162-8. PubMed ID: 9717529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor necrosis factor].
    Herrmann F; Mertelsmann R
    Dtsch Med Wochenschr; 1989 Feb; 114(8):312-6. PubMed ID: 2646094
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recombinant human tumor necrosis factor alpha (TNF): preclinical studies and results of early clinical trials].
    Płuzańska A
    Acta Haematol Pol; 1994; 25(2 Suppl 1):148-54. PubMed ID: 8067200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor necrosis factor-alpha--biological and immunologic properties].
    Chciałowski A; Targowski T; Bajera I; Jahnz-Rózyk K
    Pol Merkur Lekarski; 1997 Jun; 2(12):392-5. PubMed ID: 9424334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
    Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
    Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application.
    van Der Veen AH; ten Hagen TL; de Wilt JH; van Ijken MG; Eggermont AM
    Anticancer Res; 2000; 20(5B):3467-74. PubMed ID: 11131649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.
    Gerspach J; Pfizenmaier K; Wajant H
    Biofactors; 2009; 35(4):364-72. PubMed ID: 19484741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
    Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic enhancement of the antitumor activity of recombinant human TNF-alpha by recombinant human IFN-gamma.
    Taguchi T; Abe S; Nakano K; Matsui Y; Sohmura Y
    Cancer Detect Prev; 1988; 12(1-6):105-14. PubMed ID: 3141050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
    Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
    Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo.
    Smyth MJ; Pietersz GA; McKenzie IF
    Cancer Res; 1988 Jul; 48(13):3607-12. PubMed ID: 3259905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting.
    Corti A
    Methods Mol Med; 2004; 98():247-64. PubMed ID: 15064445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.
    Lejeune FJ
    J Clin Invest; 2002 Aug; 110(4):433-5. PubMed ID: 12189235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.